The osteoblastic regulator RANKL is clearly important in prostate cancer bone metastasis biology[42], and the clinical targeting of this pathway with denosumab, a RANKL inhibitory monoclonal antibody, has been shown to delay bone metastasis and reduce the complication rates from bone metastases in patients[49]. This evidence concerns the gene TNFSF11 and Familial prostate cancer.